12/9
08:15 am
kpti
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications [Yahoo! Finance]
Medium
Report
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications [Yahoo! Finance]
12/9
08:00 am
kpti
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Low
Report
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
12/3
07:00 am
kpti
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Medium
Report
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
12/2
07:00 am
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/28
12:06 am
kpti
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country [Yahoo! Finance]
Low
Report
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country [Yahoo! Finance]
11/25
07:00 am
kpti
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
11/22
03:37 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/20
04:05 pm
kpti
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Low
Report
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
11/18
07:12 am
kpti
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
Low
Report
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
11/18
07:00 am
kpti
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Low
Report
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
11/14
03:12 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/8
06:07 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
11/6
11:09 pm
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/6
09:17 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target raised by analysts at Piper Sandler from $4.00 to $5.00. They now have an "overweight" rating on the stock.
Low
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target raised by analysts at Piper Sandler from $4.00 to $5.00. They now have an "overweight" rating on the stock.
11/6
02:22 am
kpti
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
11/5
07:35 pm
kpti
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 [Yahoo! Finance]
Medium
Report
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 [Yahoo! Finance]
11/5
12:55 pm
kpti
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/5
10:05 am
kpti
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/5
07:30 am
kpti
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Medium
Report
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
11/4
07:20 am
kpti
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/1
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/1
08:15 am
kpti
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
10/31
08:00 am
kpti
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
High
Report
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
10/31
07:30 am
kpti
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Medium
Report
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
10/30
04:30 pm
kpti
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
High
Report
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024